Intest Res.  2020 Jul;18(3):306-314. 10.5217/ir.2019.00116.

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

• Alrajhi S
• Germain P
• Martel M
• Lakatos P
• Bessissow T
• Al-Taweel T
• Afif W

• KMID: 2504586
• DOI: http://doi.org/10.5217/ir.2019.00116

Abstract

Background/Aims
Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line screening method for the general population. Studies provided conflicting evidence on IGRA and tuberculin skin test (TST) performance in inflammatory bowel disease (IBD) patients. We assessed test concordance and the effects of immunosuppression on their performance in IBD patients.
Methods
We searched MEDLINE, Embase and Cochrane databases (2011–2018) for studies testing TST and IGRA in IBD. Primary outcome was TST and IGRA concordance. Secondary outcomes were effects of immunosuppressive therapy on performance. Immunosuppression defined as either steroids, thiopurine, methotrexate or cyclosporine use. We used the pooled random effects model to adjust for heterogeneity analyzed using (I²–Q statistics). We compared the fixed model to exclude smaller study effects.
Results
Sixteen studies (2,488 patients) were included. Pooled TST and IGRA concordance was 85% (95% confidence interval [CI], 81%–88%; P=0.01). Effects of immunosuppression were reported in 8 studies (814 patients). The odds ratio of testing positive by IGRA decreased to 0.57 if immunosuppressed (95% CI, 0.31–1.03; P=0.06). The odds ratio of testing positive by TST if immunosuppressed was 1.14 (95% CI, 0.61–2.12; P=0.69). The fixed model yielded similar results, however the negative effect of immunosuppression on IGRA reached statistical significance (P=0.01).
Conclusions
While concordance was 85% between TST and IGRA, the performance of IGRA seems to be negatively affected by immunosuppression. Given the importance of detecting latent tuberculosis prior to anti-TNF initiation, further randomized controlled trials comparing the performance of TST and IGRA in IBD patients are needed.

Keyword

Inflammatory bowel disease; Crohn disease; Colitis, ulcerative; Tuberculosis

Figure

• 

  Fig. 1. Assessment of risk of bias of studies: QUADAS-2 tool. QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2.

• 

  Fig. 2. Diagram of selection process for studies identified by search protocol.

• 

  Fig. 3. Concordance between interferon-gamma release assay and tuberculin skin test. Ev, event; Trt, treatment.

• 

  Fig. 4. OR of positive interferon-gamma release assay in immunosuppressed patients (IST+) compared to non-immunosuppressed (IST–). IST, immunosuppressive therapy; M-H, Mantel-Haenszel method.

• 

  Fig. 5. OR of positive tuberculin skin test in immunosuppressed patients (IST+) compared to non-immunosuppressed (IST–). IST, immunosuppressive therapy; M-H, Mantel-Haenszel method.

Reference

1. Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol (N Y). 2016; 12:704–707.

2. Sadowski DC, Bernstein CN, Bitton A, et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn’s disease. Can J Gastroenterol. 2009; 23:185–202.

3. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015; 148:1035–1058.

4. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis. 2005; 41–Suppl 3:S189-S193.

5. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017; 64:111–115.

6. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004; 4:761–776.

7. Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18:2034–2042.

8. Alrajhi S, Afif W, Altaweel T. TST and IGRA for tuberculosis screening in inflammatory bowel disease. PROSPERO Web site. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42016049225. Accessed January 3, 2020.

9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.

10. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155:529–536.

11. Wong SH, Ip M, Tang W, et al. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014; 20:2067–2072.

12. Kurti Z, Lovasz BD, Gecse KB, et al. Tuberculin skin test and Quantiferon in BCG vaccinated, immunosuppressed patients with moderate-to-severe inflammatory bowel disease. J Gastrointestin Liver Dis. 2015; 24:467–472.

13. Atanassova A, Kotzev I. P0308 IBD: screening for tuberculosis in patients candidates for anti‐TNF terapy in IBD. J Gastroenterol Hepatol. 2013; 28(S3):23–693.

14. Fernandez S, Riera J, Balza N, et al. P124 Use of interferon-gamma release assay (IGRA) and tuberculin skin test (TST) for tuberculosis screening in patients candidates for anti-TNF terapy in inflammatory bowel disease (IBD). J Crohns Colitis. 2013; 7(Suppl 1):S58.

15. Latorre I, Minguez S, Vilavella M, et al. Detection of IFN-gamma responses for diagnosis of tuberculosis infection in chronic inflammatory disease patients. Eur Respir J. 2011; 38(Suppl 55):p305.

16. Marano C, Hsia EC, Xu S, Sandborn W, Rutgeerts P. P0361: Interferon-gamma release assay versus tuberculin skin test in patients with moderate-to-severely active ulcerative colitis: results from the pursuit UC program. United European Gastroenterol J. 2015; 3(5 Suppl):146–687.

17. Ministro P, Machado J, Araújo R, Castanheira A, Cancela EM, Silva A. Diagnosis of latent tuberculosis in patients with inflammatory bowel disease: prospective comparison between tuberculin skin test and interferon gamma release assay (IGRA) test. Gastroenterology. 2011; 140(5 Suppl 1):S776.

18. Preda CM, Fulger LE, Gheorghe C, et al. Tuberculin skin test and Quantiferon TB Gold in Romanian BCG vaccinated, immunosuppressed patients with moderate-to-severe Crohn’s disease: a comparison with a Hungarian cohort. J Gastrointestin Liver Dis. 2016; 25:260–261.

19. Abreu C, Almeida F, Ferraz R, Dias CC, Sarmento A, Magro F. The tuberculin skin test still matters for the screening of latent tuberculosis infections among inflammatory bowel disease patients. Dig Liver Dis. 2016; 48:1438–1443.

20. Al-Taweel T, Strohl M, Pai M, et al. A study of optimal screening for latent tuberculosis in patients with inflammatory bowel disease. Dig Dis Sci. 2018; 63:2695–2702.

21. Andrisani G, Armuzzi A, Papa A, et al. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. J Gastrointestin Liver Dis. 2013; 22:21–25.

22. Bélard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON Gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011; 17:2340–2349.

23. Çekiç C, Aslan F, Vatansever S, et al. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. Ann Gastroenterol. 2015; 28:241–246.

24. Mantzaris GJ, Tsironikos D, Tzanetakou X, et al. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scand J Gastroenterol. 2015; 50:1451–1455.

25. Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17:84–90.

26. Ramos JM, Masiá M, Rodríguez JC, et al. Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold in-tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med. 2013; 13:177–186.

27. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Fixed-effect versus random-effects models. In : Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, editors. Introduction to meta-analysis. Hoboken: John Wiley & Sons Inc;2009. p. 61–102.

28. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008; 103:2799–2806.

29. Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB Gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011; 17:77–83.

30. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004; 2:309–313.

31. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med. 2010; 10:7.

32. Hopewell S, Clarke M, Mallett S. Grey literature and systematic reviews. In : Rothstein HR, Sutton AJ, Borenstein M, editors. Publication bias in meta-analysis: prevention, assessment and adjustments. Chichester: John Wiley & Sons Ltd;2005. p. 49–72.